An AIDS activist group has sued the Trump administration for not disclosing a research and development agreement with Gilead Sciences related to HIV prevention patents. This lawsuit highlights the critical need for transparency in pharmaceutical agreements, especially those involving public health and taxpayer-funded research. Developers and tech professionals should watch how this case may influence future disclosure requirements in medical research partnerships.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

![[AINews] The Unreasonable Effectiveness of Closing the Loop](/_next/image?url=https%3A%2F%2Fmedia.nemati.ai%2Fmedia%2Fblog%2Fimages%2Farticles%2F600e22851bc7453b.webp&w=3840&q=75)



